Related Experiment Video
Updated: Jul 15, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma
1Tom Baker Cancer Centre, University of Calgary Alberta, Canada.
Oncology (Williston Park, N.Y.)
|May 4, 2007
Summary
The use of adjuvant chemotherapy or chemoradiotherapy for adult soft-tissue sarcoma (ASTS) is debated. Survival rates for stage III sarcomas after local treatment are around 52-56% at 5 years.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Adjuvant therapy for adult soft-tissue sarcoma (ASTS) lacks definitive guidelines.
- Controversy exists regarding the optimal use and timing of chemotherapy and chemoradiotherapy post-surgery.
- Current research focuses on identifying appropriate patient populations for adjuvant treatment.
Framework:
- The study addresses the clinical dilemma of adjuvant treatment in high-risk ASTS.
- It defines the generally accepted target population: International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) stage III extremity or trunk sarcomas (>5 cm, grade 3/4, deep location, no metastases).
- Survival outcomes post-definitive local treatment are presented as a benchmark.
Implementation:
- This abstract outlines the current understanding and challenges in managing ASTS.
- It highlights the need for evidence-based protocols for adjuvant chemotherapy and chemoradiotherapy.
- Focus is on stage III sarcomas, a group with significant recurrence risk.
Implications:
- Clarifying adjuvant treatment protocols can improve patient outcomes in ASTS.
- Optimizing therapy selection may reduce treatment-related toxicity and improve survival.
- Further research is needed to establish the definitive role of adjuvant therapies in specific ASTS subgroups.
